The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

Moo Yong Rhee, Taehoon Ahn, Kiyuk Chang, Shung Chull Chae, Tae Hyun Yang, Wan Joo Shim, Tae Soo Kang, Jae Kean Ryu, Deuk Young Nah, Tae Ho Park, In Ho Chae, Seung Woo Park, Hae Young Lee, Seung Jea Tahk, Young Won Yoon, Chi Young Shim, Dong Gu Shin, Hong Seog Seo, Sung Yun Lee, Doo Il KimJun Kwan, Seung Jae Joo, Myung Ho Jeong, Jin Ok Jeong, Ki Chul Sung, Seok Yeon Kim, Sang Hyun Kim, Kook Jin Chun, Dong Joo Oh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia. Methods: We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria after 4 weeks of therapeutic life change were randomly assigned to the following groups. 1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3) rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks. Results: Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p<0.001). Reductions in siSBP and siDBP were not significantly different between the FMS/RSV and FMS alone groups (p=0.500 and p=0.734, respectively). After 8 weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p<0.001). The response rates of siSBP with FMS/RSV, FMS alone, and RSV alone treatments were 65.22, 55.56, and 34.09%, respectively (FMS/RSV vs. RSV, p=0.006). The LDL-C goal attainment rates with FMS/RSV, RSV alone, and FMS alone treatments were 80.43%, 81.82%, and 15.56%, respectively (FMS/RSV vs. FMS, p<0.001). Incidence of adverse drug reactions with FMS/RSV treatment was 8.33%, which was similar to those associated with FMS and RSV alone treatments. Conclusion: This study demonstrated that the co-administration of fimasartan and rosuvastatin to patients with both hypertension and hypercholesterolemia was efficacious and safe. Trial registration: ClinicalTrials.gov Identifier: NCT02166814. 16 June 2014

Original languageEnglish
Article number2
JournalBMC Pharmacology and Toxicology
Volume18
Issue number1
DOIs
Publication statusPublished - 2017 Jan 5

Fingerprint

Dyslipidemias
Hypertension
Safety
Therapeutics
fimasartan
Rosuvastatin Calcium
Hypercholesterolemia
LDL Cholesterol
Drug-Related Side Effects and Adverse Reactions

Keywords

  • Fimasartan
  • Hypercholesterolemia
  • Hypertension
  • Rosuvastatin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia. / Rhee, Moo Yong; Ahn, Taehoon; Chang, Kiyuk; Chae, Shung Chull; Yang, Tae Hyun; Shim, Wan Joo; Kang, Tae Soo; Ryu, Jae Kean; Nah, Deuk Young; Park, Tae Ho; Chae, In Ho; Park, Seung Woo; Lee, Hae Young; Tahk, Seung Jea; Yoon, Young Won; Shim, Chi Young; Shin, Dong Gu; Seo, Hong Seog; Lee, Sung Yun; Kim, Doo Il; Kwan, Jun; Joo, Seung Jae; Jeong, Myung Ho; Jeong, Jin Ok; Sung, Ki Chul; Kim, Seok Yeon; Kim, Sang Hyun; Chun, Kook Jin; Oh, Dong Joo.

In: BMC Pharmacology and Toxicology, Vol. 18, No. 1, 2, 05.01.2017.

Research output: Contribution to journalArticle

Rhee, MY, Ahn, T, Chang, K, Chae, SC, Yang, TH, Shim, WJ, Kang, TS, Ryu, JK, Nah, DY, Park, TH, Chae, IH, Park, SW, Lee, HY, Tahk, SJ, Yoon, YW, Shim, CY, Shin, DG, Seo, HS, Lee, SY, Kim, DI, Kwan, J, Joo, SJ, Jeong, MH, Jeong, JO, Sung, KC, Kim, SY, Kim, SH, Chun, KJ & Oh, DJ 2017, 'The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia', BMC Pharmacology and Toxicology, vol. 18, no. 1, 2. https://doi.org/10.1186/s40360-016-0112-7
Rhee, Moo Yong ; Ahn, Taehoon ; Chang, Kiyuk ; Chae, Shung Chull ; Yang, Tae Hyun ; Shim, Wan Joo ; Kang, Tae Soo ; Ryu, Jae Kean ; Nah, Deuk Young ; Park, Tae Ho ; Chae, In Ho ; Park, Seung Woo ; Lee, Hae Young ; Tahk, Seung Jea ; Yoon, Young Won ; Shim, Chi Young ; Shin, Dong Gu ; Seo, Hong Seog ; Lee, Sung Yun ; Kim, Doo Il ; Kwan, Jun ; Joo, Seung Jae ; Jeong, Myung Ho ; Jeong, Jin Ok ; Sung, Ki Chul ; Kim, Seok Yeon ; Kim, Sang Hyun ; Chun, Kook Jin ; Oh, Dong Joo. / The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia. In: BMC Pharmacology and Toxicology. 2017 ; Vol. 18, No. 1.
@article{80230d11b65042dcab9c12cd057fbce0,
title = "The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia",
abstract = "Background: Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia. Methods: We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria after 4 weeks of therapeutic life change were randomly assigned to the following groups. 1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3) rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks. Results: Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p<0.001). Reductions in siSBP and siDBP were not significantly different between the FMS/RSV and FMS alone groups (p=0.500 and p=0.734, respectively). After 8 weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p<0.001). The response rates of siSBP with FMS/RSV, FMS alone, and RSV alone treatments were 65.22, 55.56, and 34.09{\%}, respectively (FMS/RSV vs. RSV, p=0.006). The LDL-C goal attainment rates with FMS/RSV, RSV alone, and FMS alone treatments were 80.43{\%}, 81.82{\%}, and 15.56{\%}, respectively (FMS/RSV vs. FMS, p<0.001). Incidence of adverse drug reactions with FMS/RSV treatment was 8.33{\%}, which was similar to those associated with FMS and RSV alone treatments. Conclusion: This study demonstrated that the co-administration of fimasartan and rosuvastatin to patients with both hypertension and hypercholesterolemia was efficacious and safe. Trial registration: ClinicalTrials.gov Identifier: NCT02166814. 16 June 2014",
keywords = "Fimasartan, Hypercholesterolemia, Hypertension, Rosuvastatin",
author = "Rhee, {Moo Yong} and Taehoon Ahn and Kiyuk Chang and Chae, {Shung Chull} and Yang, {Tae Hyun} and Shim, {Wan Joo} and Kang, {Tae Soo} and Ryu, {Jae Kean} and Nah, {Deuk Young} and Park, {Tae Ho} and Chae, {In Ho} and Park, {Seung Woo} and Lee, {Hae Young} and Tahk, {Seung Jea} and Yoon, {Young Won} and Shim, {Chi Young} and Shin, {Dong Gu} and Seo, {Hong Seog} and Lee, {Sung Yun} and Kim, {Doo Il} and Jun Kwan and Joo, {Seung Jae} and Jeong, {Myung Ho} and Jeong, {Jin Ok} and Sung, {Ki Chul} and Kim, {Seok Yeon} and Kim, {Sang Hyun} and Chun, {Kook Jin} and Oh, {Dong Joo}",
year = "2017",
month = "1",
day = "5",
doi = "10.1186/s40360-016-0112-7",
language = "English",
volume = "18",
journal = "BMC pharmacology & toxicology",
issn = "2050-6511",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

AU - Rhee, Moo Yong

AU - Ahn, Taehoon

AU - Chang, Kiyuk

AU - Chae, Shung Chull

AU - Yang, Tae Hyun

AU - Shim, Wan Joo

AU - Kang, Tae Soo

AU - Ryu, Jae Kean

AU - Nah, Deuk Young

AU - Park, Tae Ho

AU - Chae, In Ho

AU - Park, Seung Woo

AU - Lee, Hae Young

AU - Tahk, Seung Jea

AU - Yoon, Young Won

AU - Shim, Chi Young

AU - Shin, Dong Gu

AU - Seo, Hong Seog

AU - Lee, Sung Yun

AU - Kim, Doo Il

AU - Kwan, Jun

AU - Joo, Seung Jae

AU - Jeong, Myung Ho

AU - Jeong, Jin Ok

AU - Sung, Ki Chul

AU - Kim, Seok Yeon

AU - Kim, Sang Hyun

AU - Chun, Kook Jin

AU - Oh, Dong Joo

PY - 2017/1/5

Y1 - 2017/1/5

N2 - Background: Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia. Methods: We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria after 4 weeks of therapeutic life change were randomly assigned to the following groups. 1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3) rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks. Results: Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p<0.001). Reductions in siSBP and siDBP were not significantly different between the FMS/RSV and FMS alone groups (p=0.500 and p=0.734, respectively). After 8 weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p<0.001). The response rates of siSBP with FMS/RSV, FMS alone, and RSV alone treatments were 65.22, 55.56, and 34.09%, respectively (FMS/RSV vs. RSV, p=0.006). The LDL-C goal attainment rates with FMS/RSV, RSV alone, and FMS alone treatments were 80.43%, 81.82%, and 15.56%, respectively (FMS/RSV vs. FMS, p<0.001). Incidence of adverse drug reactions with FMS/RSV treatment was 8.33%, which was similar to those associated with FMS and RSV alone treatments. Conclusion: This study demonstrated that the co-administration of fimasartan and rosuvastatin to patients with both hypertension and hypercholesterolemia was efficacious and safe. Trial registration: ClinicalTrials.gov Identifier: NCT02166814. 16 June 2014

AB - Background: Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia. Methods: We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria after 4 weeks of therapeutic life change were randomly assigned to the following groups. 1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3) rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks. Results: Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p<0.001). Reductions in siSBP and siDBP were not significantly different between the FMS/RSV and FMS alone groups (p=0.500 and p=0.734, respectively). After 8 weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p<0.001). The response rates of siSBP with FMS/RSV, FMS alone, and RSV alone treatments were 65.22, 55.56, and 34.09%, respectively (FMS/RSV vs. RSV, p=0.006). The LDL-C goal attainment rates with FMS/RSV, RSV alone, and FMS alone treatments were 80.43%, 81.82%, and 15.56%, respectively (FMS/RSV vs. FMS, p<0.001). Incidence of adverse drug reactions with FMS/RSV treatment was 8.33%, which was similar to those associated with FMS and RSV alone treatments. Conclusion: This study demonstrated that the co-administration of fimasartan and rosuvastatin to patients with both hypertension and hypercholesterolemia was efficacious and safe. Trial registration: ClinicalTrials.gov Identifier: NCT02166814. 16 June 2014

KW - Fimasartan

KW - Hypercholesterolemia

KW - Hypertension

KW - Rosuvastatin

UR - http://www.scopus.com/inward/record.url?scp=85008413171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008413171&partnerID=8YFLogxK

U2 - 10.1186/s40360-016-0112-7

DO - 10.1186/s40360-016-0112-7

M3 - Article

C2 - 28057081

AN - SCOPUS:85008413171

VL - 18

JO - BMC pharmacology & toxicology

JF - BMC pharmacology & toxicology

SN - 2050-6511

IS - 1

M1 - 2

ER -